Our History
| Apr. 1999 | Founded in Hodogaya, Yokohama. |
| Apr. 1999 | Started collaborative research with Hitachi Software Engineering Co., Ltd. [currently Hitachi, Ltd.]. |
| Aug. 1999 | Marketed the first made-in-Japan DNA chip “Yeast Chip ver. 1.0.” |
| Dec. 2001 | Moved headquarter to Science Frontier District, Tsurumi-ku, Yokohama. |
| Seq. 2002 | Started the new product “AceGene Human Oligo Chip 30K”. |
| Nov. 2002 | Corporate name changed to DNA Chip Research Inc. |
| Jun. 2003 | Split of 1 common stock into 2 shares. |
| Jun. 2003 | Started the new product “Ace Gene Mouse Oligo Chip 30K”. |
| Mar. 2004 | Announced IPO on Tokyo Stock Exchange MOTHERS (Capital increased to 600 million Japanese Yen). |
| Jun. 2004 | Started the new product “Ace Gene 30K on One Chip Version”. |
| Seq. 2004 | Started the new product “Hyper Gene Rat cDNA Chip”. |
| May. 2005 | Split of 1 common stock into 2 shares. |
| Nov. 2005 | Developed a new amination reagent and signed a license agreement with Sigma-Aldrich Japan. |
| Apr. 2006 | Started the new product services “AceGene Premium Human”. |
| May. 2006 | Started the new product “3D-Gene with Probe Bank”. |
| Jun. 2006 | First issuance of convertible bonds: Issued the first series of unsecured convertible bonds with stock acquisition rights. |
| Nov. 2006 | Formed strategic alliance on microarray business with Agilent Technologies Inc., USA. |
| Dec. 2006 | Completed the full conversion of the first series of unsecured convertible bonds with stock acquisition rights into shares. |
| May. 2007 | Started new product services “ConPath Chip” and “ConPath Navigator”. |
| Aug. 2007 | Marketed “Hyb-Teacher”, an educational microarray genotyping kit for students. |
| Nov. 2007 | Received 24th Industrial Technology Development Incentive Award from Kanagawa Prefecture for development of “Probe Bank”. |
| Mar. 2008 | Transferred the Genome Analysis Department from HuBit Genomics Co., Ltd. |
| Mar. 2008 | Started Clinical Trial using “RNA Check” to assess the efficacy of DMARD's (Disease Modifying Anti-Rheumatic Drugs). |
| Mar. 2008 | Started service of “Mamma Print”, a risk assessment test on prognosis of Breast Cancer. |
| Apr. 2009 | Accredited with Privacy Mark. |
| Jul. 2010 | Formed strategic alliances with TAKEDA RIKA KOGYO Co., Ltd. and WaferGeneBiosystems, Inc. Started the Exclusive Sales and Contract Service for the Next-Generation Ultra-High-Speed Ultra-High Sensitivity Real-Time PCR System (SmartChip) in Japan. |
| Jan. 2011 | Formed a business alliance with RIKEN GENESIS Co., Ltd. for genetic analysis services. |
| Mar. 2011 | Marketed “iCIS-crdb”, a gene expression data service for clinical research. |
| Apr. 2011 | Marketed “iRIS”, a rheumatoid arthritis electronic survey system in clinical settings. |
| Dec. 2011 | Marketed “TBONE EX KIT”, a DNA extraction kit for hard tissue such as tooth and bone. |
| Oct. 2013 | Split of 1 common share into 100 shares and adoption of a unit stock system. |
| Oct. 2013 | Formed strategic alliance with Agilent Technologies Inc., USA on Next Generation Sequence analysis service. |
| Aug. 2014 | Transferred to the 2nd Section of the Tokyo Stock Exchange. |
| Nov. 2014 | Signed capital and business alliance agreement with Enplas Corporation (Capital increased to 1.4 billion Japanese yen). |
| Mar. 2015 | Original research paper published on identification of miRNA that regulates tumorigenesis of glioma, in collaboration with Ehime University Graduate School of Medicine and Hokkaido University. |
| Apr. 2015 | Launched liquid biopsy companion diagnostic test DiVA-EGFR Check to detect rare mutants in plasma cell-free DNA of lung cancer patients. |
| Apr. 2015 | Developed and published a set of external RNA standards and control probes, which enable multi-platform calibration and data validation among microarray, qPCR and NGS (part of a JMAC (Japan Multiplex bio-Analysis Consortium) project). |
| May. 2015 | Patent awarded for Biomarker and Method used for Determining Rheumatoid Arthritis Disease Activity (Patent Number: 5676777). |
| Nov. 2015 | Moved the research laboratory and office to Minato ward, Tokyo. |
| Jun. 2017 | Transitioed from a company with a Board of Corporate Auditors to a company with an Audit and supervisory Committee. |
| May. 2020 | Cancelled the capital and business alliance agreement with Enplas Corporation. |
| Nov. 2021 | Formed a business alliance with Genemetrix LLC for the lung cancer compact panel business. |
| Oct. 2022 | Established a medical laboratory in Kawasaki City, Kanagawa. |
| Jan. 2023 | Signed a capital and business alliance agreement with Mitsui Chemicals, Inc. |
| Oct. 2024 | Moved the laboratory to Kawasaki City, Kanagawa. |
| Apr. 2025 | Mitsui Chemicals, Inc. concludes a public Takeover bid (TOB). |
| Jun. 2025 | Stock consolidated through the Takeover bid (TOB). |
| Jun. 2025 | Transitioned from a company with an Audit and Supervisory Committee to a company with a Board of Corporate Auditors. |
| Jun. 2025 | Delisted on the Tokyo Stock Exchange, Standard Market Became a corporate group company of Mitsui Chemicals, Inc. |